Year in Review

Immune-mediated kidney disease in 2017: Progress in mechanisms and therapy for immunological kidney disease

In 2017, progress was made in several aspects of immune-mediated kidney disease. Mechanistic studies provided new insights into the underlying signals that confer risk to, or protection from, immune pathways, whereas new approaches to the treatment of immunological kidney disease will hopefully translate into a move away from the use of toxic corticosteroids.

  • Subscribe to Nature Reviews Nephrology for full access:

    $199

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    et al. Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells. Nature 545, 243–247 (2017).

  2. 2.

    & The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity. Kidney Int. 56, 1638–1653 (1999).

  3. 3.

    et al. Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. J. Am. Soc. Nephrol. 15, 2103–2114 (2004).

  4. 4.

    et al. Gene-specific DNA methylation changes predict remission in patients with ANCA-associated vasculitis. J. Am. Soc. Nephrol. 28, 1175–1187 (2017).

  5. 5.

    et al. Genetically distinct subsets within ANCA-associated vasculitis. N. Engl. J. Med. 367, 214–223 (2012).

  6. 6.

    et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 318, 432–442 (2017).

  7. 7.

    et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet 389, 2117–2127 (2017).

  8. 8.

    , & Biologics for the treatment of autoimmune renal diseases. Nat. Rev. Nephrol. 12, 217–231 (2016).

  9. 9.

    et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J. Am. Soc. Nephrol. 28, 2756–2767 (2017).

  10. 10.

    et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J. Am. Soc. Nephrol. 25, 225–231 (2014).

Download references

Author information

Affiliations

  1. Centre for Inflammatory Diseases, Monash Medical Centre; and at the Department of Nephrology, Monash Medical Centre, 246 Clayton Road, Clayton, Melbourne, Victoria 3168, Australia.

    • Stephen R. Holdsworth
    •  & A. Richard Kitching

Authors

  1. Search for Stephen R. Holdsworth in:

  2. Search for A. Richard Kitching in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Stephen R. Holdsworth.